Shares of the biotech Moderna were up on Wednesday, as the Trump administration’s shifting position on messenger RNA-based ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Global vaccine stocks in focus as the U.S. government plans to phase out investment for mRNA vaccine development activities.

Life science companies developing bird flu vaccines and antivirals are gaining attention as the avian influenza subtype H5N1 becomes an increasing concern. The United States is in the midst of an ...

The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...

(Reuters) -Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S. Health Secretary Robert F. Kennedy Jr.'s surprising decision to fire all 17 members of a key expert ...

The signs of a potential bird flu transmission have provided some respite to these vaccine-focused stocks, especially for those involved in the COVID-19 vaccine roll-out.

Moderna's stock fell 13% to $27.18 in early trading while Novavax's stock slid 7% to $6.50. Shares of Vaxcyte sank 55% to $31.60 and shares of Sarepta Therapeutics slipped 7% to $65.71.

Danger Is Approaching for Coronavirus Vaccine Stocks As the race for a Covid-19 vaccine enters the final stretch, investors should be more wary of common drug development pitfalls By Charley Grant ...

Quality control errors led millions of potential vaccines to be ruined. For Emergent BioSolutions, Feb. 8 was a day to revel in their success -- at least as far as the public was concerned ...